Skip to content
drillr.ai

VCEL

Vericel Corporation

NASDAQ · USHealthcareBiotechnology
$45.88-1.63%

Price as of Jul 20, 2026

VCEL news

Vericel Corporation news

A server-rendered, paginated timeline of the latest available company news.

  1. Regenerative Medicine’s Next Chapter: Inside the Race to Make the Body Rebuild Itself

    Issued on behalf of Conexeu Sciences Inc. A sector analysis of regenerative medicine — the science of restoring tissue rather than merely replacing it — and where a new generation of platform companies is trying to fit in. NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Biotech Insider (https://www.globenewswire.com/Tracker?data=DVJrA7TbaSHoWZvxL--foowzGT77LPmehJOoPML5DOle2A_51c37s7Kzcz-Az7mGx8adJ7a9Rw4eGl7kGwyE-VQJuYIGzG8LodVu_rogI6Q=) News Commentary — For most of medical history, the human body

    Globe Newswire ·

  2. The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It

    Issued on behalf of Conexeu Sciences Inc. A new generation of tissue companies is betting that the future of wound care and reconstruction isn't a better patch — it's a material that helps the body regrow itself. One newly public name just took a concrete step toward proving it. NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — For most of medical history, the body's inability to regrow lost tissue has been treated as a fact to be managed rather than a pro

    Globe Newswire ·

  3. Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026

    BURLINGTON, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16(th), 2026. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel Corporation Vericel is a leading pro

    Globe Newswire ·

  4. The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself

    Issued on behalf of Conexeu Sciences Inc. A biotech debut out of Reno is betting that the next wave of medicine won’t replace tissue — it’ll grow it back. NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Energy Metal News (https://www.globenewswire.com/Tracker?data=g1stipmRsJemNbBtz8XSdT_Lga8UDW5y6_2-KXPnXjC928PkekN_wrMSqa3Y1clwUU_IJhJEUoihNc_i6wwAMVk2qfLmf-FOo-x22Y2ZGTs=) News Commentary — Somewhere between a 3D printer, a stem cell lab, and an operating room, a quiet shift has been building in med

    Globe Newswire ·

  5. Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance

    Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91% Gross Margin of 72% and Adjusted EBITDA Growth of 195% Free Cash Flow of $15.1 Million Full-Year 2026 Revenue Guidance Raised by $10 Million to $326 to $336 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets,

    Globe Newswire ·

  6. MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

    MediWound Reports BARDA Contract Award to Vericel for NexoBrid(®) Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair, today announced that Vericel Corporation (NASDAQ:VCEL), its exclusive distributor of NexoBrid(®) in North America, has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authorit

    Globe Newswire ·

  7. Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid

    CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for the procurement of NexoBrid(®), establishmen

    Globe Newswire ·

  8. Vericel to Present at Multiple Upcoming Investor Conferences

    CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the following investor conferences: * TD Cowen 46(th) Annual Healthcare Conference on Wednesday, March 4(th), 2026 * Leerink Partners 2026 Global Healthcare Conference on Tuesday, March 10(th), 2026 A webcast of the presentations will be available on the Investor Relations sect

    Globe Newswire ·